Parasitic Arthritis

  • Javier Dario Márquez-Hernández


Parasitic infections are a public health problem worldwide, most of them considered neglected tropical diseases (NTDs). Poor hygiene habits, the consumption of non-potable water, and eating badly cooked or raw food, together with immunosuppressed states due to diseases or medications, are the main risk factors for acquiring them. Osteomuscular compromise due to parasitic infections should be considered in bizarre atypical manifestations with eosinophilia that do not improve with conventional treatment in endemic areas or travelers.

The discovery of better diagnostic techniques and more effective treatments makes it possible to eradicate with the implementation of adequate regulations and policies.


Protozoan Amoeba, Giardia Leishmania, Plasmodium Cryptosporidium Helminthes Flatworms Platyhelminthes Trematodes Cestodes Nematodes 


  1. 1.
    Marquez J, Espinoza LR. Mycobacterial, brucellar, fungal and parasithic arthritis. In: Hochberg MC, editor. Rheumatology. 7th ed. Philadelphia: Elsevier; 2019. p. 943–54.Google Scholar
  2. 2.
    Ely LW, Reed AC, Wyckoff HA. The amoeba as the cause of the second great type of chronic arthritis preliminary note. Cal State J Med. 1921;V:XIX,415.Google Scholar
  3. 3.
    Restrepo JC, Molina MP. Colonic perforation due to amebic invasion colitis during anti-TNF therapy for spondyloarthritis. Rev Bras Reumatol. 2014;54(6):483–5.CrossRefGoogle Scholar
  4. 4.
    Bouzid M, Hunter PR, Chalmers RM, Tyler KM. Cryptosporidium pathogenicity and virulence. Clin Microbiol Rev. 2013;26(1):115–34.CrossRefGoogle Scholar
  5. 5.
    Alemu G, Alelign D, Abossie A. Prevalence of opportunistic intestinal parasites and associated factors among HIV patients while receiving ART at Arba Minch Hospital in South Ethiopia: a crossectional study. Ethiop J Health Sci. 2018;28(2):147–56.CrossRefGoogle Scholar
  6. 6.
    Painter JE, Gargano JW, Collier SA, Yoder JS. Giardiasis surveillance—United States, 2011-2012. Centers for Disease Control and Prevention. MMWR Suppl. 2015;64(3):15–25.PubMedGoogle Scholar
  7. 7.
    Gibney Kb O’TJ, Sinclair M, Leder K. Disease burden of selected gastrointestinal pathogens in Australia 2010. Int J Infect Dis. 2014;28:176–85.CrossRefGoogle Scholar
  8. 8.
    Painter JE, Collier SA, Gargano JW. Association between Giardia and arthritis or joint pain a large health insurance cohort: could it be reactive arthritis? Epidemiol Infect. 2017;145(3):471–7.CrossRefGoogle Scholar
  9. 9.
    Mace KE, Argui PM, Tan KR. Malaria surveillance-United States, 2015. MMWR Surveill Summ. 2018;67(4):1–28.CrossRefGoogle Scholar
  10. 10.
    Lewis JM, Clifford S, Nsutebu E. Toxoplasmosis in immunosuppressed patients. Rheumatology. 2015;54:1939–40.CrossRefGoogle Scholar
  11. 11.
    Hosseininejad Z, Sharif M, Sarvi S, Amouei A, Hosseini SA, et al. Toxoplasmosis seroprevalence in rheumatoid arthritis patients: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2018;12(6):e0006545. Scholar
  12. 12.
    Masocha W, Kristensson K. Human African trypanosomiasis: how do the parasites enter and cause dysfunctions of the nervous system in murine models? Brain Res Bull. 2018 . S0361-9230(18)30226-0. [Epub ahead of print]; Scholar
  13. 13.
    Bennett C, Strayli A, Haselow D, Weinstein S, Taffner R, et al. Chagas disease surveillance activities-seven States, 2017. MMWR. 2018;67(26):738–41.PubMedGoogle Scholar
  14. 14.
    McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald VJ, et al. Schistosomiasis. Nat Rev Dis Primers. 2018;4(1):13. Scholar
  15. 15.
    Rakotomalala HN, Ranaivoarison MV, Andraianjafison F, Ralandison DS. Bilharzialarthropathy: rare cause of chronic arthritis in tropical areas. Eur J Rheumatol. 2017;4:229–30.CrossRefGoogle Scholar
  16. 16.
    Alim B, Centinel S, Servi MA, Bostanci F, Bingol MO. The case of reactive arthritis secondary to Echinococcus infestation. Case Rep Rheumatol. 2017;3293060 Scholar
  17. 17.
    Eckert J, Deplazes P. Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev. 2004;17(1):107–35.CrossRefGoogle Scholar
  18. 18.
    Alishani M, Sherifi K, Rexhepi A, Hamidi A, Armua-Fernandez M, et al. The impact of socio-cultural factors on transmission of Taenia spp. and Echinoccusgranulosus in Kosovo. Parasitology. 2017;144(13):1736–42.CrossRefGoogle Scholar
  19. 19.
    Samorek-Pierog M, Jacek K, Cencek T. Identification and control of source of Taenia solium infection –the attempts to eradicate the parasite. J. Vet Res. 2018;62:27–34.CrossRefGoogle Scholar
  20. 20.
    Symeonidou I, Arsenopulos K, Tzilves D, Soba B, Gabriel S, et al. Human taeniasis/cysticercosis: a potentially emerging parasitic disease in Europe. Ann Gastroenterol. 2018;31(4):406–12.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Dsilva G, Kulkarni V, Aher S. An uncommon manifestation of a common disease. Ann Parasitol. 2017;63(4):357–60.PubMedGoogle Scholar
  22. 22.
    Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloidesstercolaris infection. Ann Pharmacother. 2007;41(12):1992–2001.CrossRefGoogle Scholar
  23. 23.
    Brandelero E, Dambros BP, Goncalves EM, Pagliusi VL, Moro A, et al. Occasional digestive hemorrhage in children due to Strongyloidiasisi importance of parasitologic testing. Rev Paul Pediatr. 2019;371:1,00013. Scholar
  24. 24.
    Mohanty S, Samprathi M, Parija S. Reactive arthritis associated with Strongyloides stercolaris: report of an uncommon relation. Trop Parasitol. 2017;7(2):117–9.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Yanik K, Karadag A, Odabasi H, Unal N, Altintop L, et al. Strongyloides stercolaris in a patient with ankylosing spondylitis: case report. Turkiye Parazitol Derg. 2013;37(2):143–6.CrossRefGoogle Scholar
  26. 26.
    Khaliq MF, Ihle R, Perry J. Immunosuppression with anti-tumour Necrosis Factor Therapy leading to Strongyloides Hyperinfection Syndrome. Case Rep Infect Dis. 2018:6341680. Scholar
  27. 27.
    Cleveland CA, Garret KB, Cozad RA, Williams BM, Murray MH, et al. The wild world of Guinea Worms: a review of the genus Dracunculus in wildlife. Int J Parasitol Parasites Wildl. 2018;7:289–300.CrossRefGoogle Scholar
  28. 28.
    Hopkins DR, Ruiz-Tiben E, Ebherhard ML, Weiss A, Withers PC Jr, et al. Dracunculiasis eradication: are we there yet? Am J Trop Med Hyg. 2018;99(2):388–95.CrossRefGoogle Scholar
  29. 29.
    Shetty JB, Kini S, Phulpagar M, Meenakshi B. Coinfection of malaria and filarial with unusual crisis form. Trop Parasitol. 2018;8(1):44–6.CrossRefGoogle Scholar
  30. 30.
    Ramaiah KD, Ottesen EA. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis. 2014;8(11):e3319. Scholar
  31. 31.
    Lee JH, Jang JW, Cho CH, Kim JY, Han ET. False positive results for rapid diagnostic test for malaria in patients with rheumatoid factor. J Clin Microbiol. 2014;52(10):3784–7.CrossRefGoogle Scholar
  32. 32.
    Rahimi-Esboei B, Zarei M, Mohebali M, Valian HK, Shojaee S, et al. Serologic test of IgG avidity for diagnosis of ocular toxoplasmosis. Korean J Parasitol. 2018;56(2):147–52.CrossRefGoogle Scholar
  33. 33.
    Sguassero Y, Robert KN, Harvey GB, Comandé D, Ciapponi A, et al. Course of serological tests in treated subjects with chronic Trypanozomacruzi infection: a systemic review and meta-analysis of individual participant data. Int J Infect Dis. 2018;73:93–101.CrossRefGoogle Scholar
  34. 34.
    Lappalainen M, Hedman K. Serodiagnosis of toxoplasmosis. Ann 1st Super Sanita. 2004;40(1):81–8.Google Scholar
  35. 35.
    Carranza-Rodriguez C, Prez-Arellano JL. Images in clinical tropical medicine. Radiological detection of Dracunculus medinensis. Am J Trop Med Hyg. 2018;98(5):1218–9.CrossRefGoogle Scholar
  36. 36.
    Hjollo T, Bratland E, Steinsland H, Radunovic M, Langeland N. Longitudinal Cohort study of serum antibody responses towards Giardia lamblia variant-specific surface proteins in a non-endemic area. Exp Parasitol. 2018;191:66–72.CrossRefGoogle Scholar
  37. 37.
    Doury P. Parasitic rheumatism. Arthritis Rheum. 1981;24:638–9.CrossRefGoogle Scholar
  38. 38.
    Scepanovic P, Alanio C, Hammer C, Hodel F, Berdstedt J. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018;10(1):59. Scholar
  39. 39.
    Debnath A, Personage D, Andrade R, He C, Cobo E, et al. A high throughput drug screen for Entamoebahistolytica identifies a new lead and target. Nat Med. 2012;18(6):956–60.CrossRefGoogle Scholar
  40. 40.
    Andrade RM, Reeds SL. New drug targeting protozoan parasites: the role of thioredoxin reductase. Front Microbiol. 2015;6:975. Scholar
  41. 41.
    Muller J, Hemphill A, Muller N. Physiological aspects of nitro drug resistance inGiardia lamblia. Int J Parasitol Drugs Drug Resist. 2018;8:271–7.CrossRefGoogle Scholar
  42. 42.
    Chavez MA, White AC. Novel treatment strategies and drugs in development for cryptosporidium. Expert Rev Anti-Infect Ther. 2018;17:1–7.Google Scholar
  43. 43.
    Lee S, Beamer G, Tzipori S. The piglet acute diarrhea model for evaluating efficacy of treatment and control of cryptosporidiosis. Hum Vaccin Immunother. 2018;
  44. 44.
    Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, et al. A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. Science. 2017;358(6362):522–8.CrossRefGoogle Scholar
  45. 45.
    Soares R, Ribeiro L, Abramo C, Costa G, Soares E, et al. What do we know about the role of regulatory B cells (Breg) during course of infection of two major parasitic diseases malaria and leishmaniasis? Pathog Glob Health. 2017;111(3):107–15.CrossRefGoogle Scholar
  46. 46.
    Girard MC, Acevedo GR, López L, Ossowski MS, Piñeyro MD, et al. Evaluation of the immune response against Trypanosome cruzi cytosolic Tryparedoxin Peroxidase in human natural infection. Immunology. 2018;155(3):367–8.CrossRefGoogle Scholar
  47. 47.
    Scarim CB, Jornada DH, Chelucci RC, de Almeida L, Dos Santos JL, et al. Current advances in drug discovery for Chagas disease. Eur J Med Chem. 2018;155:824–38.CrossRefGoogle Scholar
  48. 48.
    Gyapong JO, Owusu IO, Vroom FB, Mensah EO, Gyapong M. Elimination of Lymphatic filariasis: current perspective on mass drug administration. Res Rep Trop Med. 2018;9:25–33.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Martinez-Perez A, Roure Doaez S, Belhassen-Garcia M, Torrua SD, Perez-Arellano JL. Management of severe strongyloidiasis attended at reference centers in Spain. PLos Negl Trop Dis. 2018;12(2):e0006272. Scholar
  50. 50.
    Velasco-Tirado V, Alonso-Sardon M, Lopez-Bernus A, Romero-Alegria A, Burguillo FJ, et al. Medical treatment of cystic echinococcosis: systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):306. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Javier Dario Márquez-Hernández
    • 1
  1. 1.Internal Medicine, RheumatologyHospital Pablo Tobón Uribe – Universidad CESMedellinColombia

Personalised recommendations